In 2023, a 12-year-old girl named Kendric Cromer became one of the first people in the world to receive CRISPR gene editing therapy for sickle cell disease. Within months, the excruciating pain crises that had hospitalized her throughout childhood disappeared. By early 2024, she was playing volleyball and living without the disease that had defined her life. Two years later, she remains healthy—and she's no longer alone.

The First Wave of Approved Treatments

December 8, 2023 marked the moment CRISPR moved from laboratory promise to clinical reality. The FDA approved Casgevy, the first therapy using CRISPR/Cas9 technology, for treating sickle cell disease. The results from clinical trials justified the enthusiasm: 93.5% of patients achieved freedom from severe pain crises for at least 12 consecutive months. For a disease affecting 100,000 Americans—mostly African Americans and Hispanic Americans—with limited treatment options beyond painful bone marrow transplants, this represented a genuine breakthrough.

The treatment works by reactivating fetal hemoglobin, a form of the oxygen-carrying protein that naturally switches off after birth. In sickle cell disease, adult hemoglobin becomes misshapen, causing red blood cells to form crescents that block blood flow and trigger agonizing pain. By editing patients' blood stem cells to produce fetal hemoglobin again, CRISPR essentially gives the body an alternative that works properly.

The process isn't simple. Doctors extract a patient's blood stem cells, edit them in a laboratory using CRISPR's molecular scissors to cut DNA at precise locations, then infuse the modified cells back after chemotherapy wipes out the original bone marrow. It's a one-time treatment, but it requires weeks of hospitalization and carries risks including low blood cell counts and, in some cases, potential for blood cancers that require lifelong monitoring.

From One-Size-Fits-All to Custom Corrections

The real paradigm shift came in February 2025, when doctors at Children's Hospital of Philadelphia treated an infant known as Baby KJ with a CRISPR therapy designed specifically for him. KJ had carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disorder that prevents the body from processing ammonia. Without treatment, toxic ammonia levels cause brain damage and death.

Rather than using the standard CRISPR/Cas9 approach, researchers employed base editing—a more refined technique that changes individual genetic letters without cutting both strands of DNA. They identified KJ's specific mutation, designed a custom therapy, manufactured it, and delivered it to his liver using lipid nanoparticles, all within six months.

This timeline matters enormously. Thousands of genetic diseases exist, many affecting only handfuls of patients worldwide. Traditional drug development can't justify the cost for such small populations. But if researchers can design personalized CRISPR therapies in months rather than years, the economics change. The approach published in The New England Journal of Medicine in May 2025 provides a template that could theoretically apply to any genetic disease with a known mutation.

The Expanding Target List

CRISPR research has moved well beyond blood disorders. Clinical trials are currently testing the technology against B-cell and T-cell lymphomas, using edited immune cells to attack cancer. Other trials target autoimmune diseases like lupus and scleroderma, where misfiring immune systems attack healthy tissue.

Cardiovascular applications show particular promise. Researchers are editing genes that control cholesterol production and lipid metabolism, potentially offering permanent solutions for inherited conditions that cause heart attacks in young adults. Type 1 diabetes trials aim to protect insulin-producing cells from immune attack.

The breadth of diseases under investigation reflects CRISPR's fundamental advantage: it targets root causes rather than managing symptoms. A child with sickle cell disease might require lifelong blood transfusions, pain medications, and frequent hospitalizations. A single CRISPR treatment could eliminate the disease entirely.

The Cancer Warning Nobody Expected

In late 2024, regulators added a black box warning to Lyfgenia, one of the approved sickle cell treatments, after some patients developed blood cancers. The warning complicated what should have been a celebration. How could a cure cause cancer?

The answer involves how the therapy inserts genetic material. Unlike Casgevy's CRISPR approach, Lyfgenia uses a viral vector that can randomly integrate into the genome, occasionally disrupting genes that control cell growth. This doesn't mean CRISPR itself causes cancer—Casgevy hasn't shown this problem—but it highlights that gene editing carries inherent risks when manipulating the fundamental code of life.

These risks don't invalidate the technology. Chemotherapy causes cancer too, yet remains essential for treating many diseases. The question isn't whether CRISPR is perfectly safe, but whether its benefits outweigh its risks for specific conditions. For someone with severe sickle cell disease facing a lifetime of suffering, a small cancer risk may be acceptable. For someone with a mild genetic condition, the calculation changes.

When Elimination Becomes Possible

The word "eliminate" deserves scrutiny. CRISPR can eliminate genetic diseases from individual patients by correcting their cells. But eliminating diseases from the human population requires editing embryos or reproductive cells—germline editing that would pass changes to future generations.

Most countries have banned germline editing in humans, though China's He Jiankui infamously violated this prohibition in 2018 when he created gene-edited babies. The scientific consensus opposes germline editing until safety improves and society resolves profound ethical questions about permanently altering human heredity.

Yet somatic editing—changing cells in living patients—could still dramatically reduce disease prevalence. If most people with sickle cell disease receive CRISPR therapy and live healthy lives, they can have children who inherit the condition but can themselves receive treatment. Over generations, better treatment reduces suffering even without germline changes.

The Access Problem Medicine Keeps Ignoring

Casgevy costs $2.2 million per patient. Even with insurance coverage, this price point restricts access to major medical centers in wealthy countries. Sickle cell disease disproportionately affects populations in sub-Saharan Africa, where millions lack basic healthcare, let alone gene editing.

The personalized approach could paradoxically improve access for rare diseases. Manufacturing custom therapies for individual patients might cost less than developing mass-market drugs for small populations. But this assumes regulatory frameworks adapt to approve individualized treatments—currently, each therapy requires separate clinical trials and approval processes.

Dr. Kiran Musunuru, who led KJ's treatment, argues that "the promise of gene therapy that we've heard about for decades is coming to fruition." He's right that the technology works. Whether it reaches the patients who need it most remains an open question that science alone cannot answer.